– Apollon has signed more than a dozen tripartite agreements with CLA licensed growers

– Apollon founded the Apollon Kannabiz Cooperative to work with local Jamaican farmers

LONDON, January 10, 2022 / PRNewswire / – Apollon Formulies plc (AQSE: APOL), (“Apollon” or the “Company”), a UK-based international medical cannabis pharmaceutical company trading in the growing AQSE market, is pleased to announce that The company has more than a dozen tripartite agreements with licensed growers of the Cannabis License Authority (CLA) that provide access to constant availability of large quantities of high quality, fresh crops of cannabis buds used by Apollon to process and manufacture medicinal cannabis products for Expedite Patients, Clinical Trials, and Export.

Director of Enforcement and Oversight at the Cannabis Licensing Authority (CLA), Believe Grahamsaid recently in a Jamaica Information Service (JIS) think tank that “by insisting on a standard for our licensees and those interested in joining our local market, we show that we are on an international scale operate as we apply best practices for global industry “. Ms. Graham continued, “The CLA operates a closed loop system characterized by a tripartite agreement that is fundamental to upholding its industry integrity. The tripartite agreement ensures that the cultivated ganja (cannabis) is sold to another licensee. ”¹

In addition, the company created the Apollon Kannabiz Cooperative to ensure traditional breeders are not excluded from the regulated medical cannabis system. Apollon is of the opinion that the local farmers should not only “grow for us”, but should also be given the opportunity to “grow with us”.

Minister of State in the Ministry of Industry, Trade, Agriculture and Fisheries, Hon. Floyd Green, who spoke at the official opening of Apollon Formulies Limited in Westmoreland, Jamaica, in October 2019, welcomed the community-based initiative, Apollon Kannabiz Cooperative, through which traditional ganja farmers can enter the legal industry. Darling. Floyd Green “Apollon is indeed aware of the need to develop a holistic sector that does not overlook the traditional farmer’s sustainable path.” ²

“We are pleased that so many CLA licensed growers have signed tripartite agreements with the company expressing their interest and willingness to grow and provide significant quantities of high quality, freshly harvested cannabis buds used by Apollon for processing and manufacturing large Sets of. it uses medicinal cannabis products that will greatly expedite and expand our inventory for patients, clinical trials and export, “said Stephen D. Barnhill, MD, CEO of Apollon Formulies, plc.” We also recognize and appreciate the experience and commitment of the traditional Jamaican ganja farmers and look forward to expanding the Apollon Kannabiz Cooperative to create jobs and income to enable local farmers to enjoy better lives for themselves and their families. “

Paul Burke, CEO of Apollon Formulies Jamaica Limited, stated, “Apollon’s mission is to reposition Jamaica’s medical cannabis industry in terms of science, research and development, product manufacturing, affordable patient care and legal export, while becoming an industry leader in global pharmaceutical and nutraceutical medical Cannabis room. ”

References:

¹ https://mckoysnews.com/cla-urges-compliance-with-regulations/

² https://jis.gov.jm/cannabis-can-provide-big-boost-for-tourism/

Further information

on July 19, 2021, Apollon announced that its proprietary medicinal cannabis formulations have been shown in independent third-party clinical laboratory tests to be effective in killing both hormone-resistant and hormone-sensitive prostate cancer cells in 3D cell cultures through direct cytotoxicity.

June 28, 2021, Apollon announced that its proprietary medicinal cannabis formulations have been shown to be effective in killing triple negative breast cancer cells in 3D cell cultures through direct cell cytotoxicity in independent third-party clinical laboratory tests.

May 18, 2021, Apollon announced that its proprietary medicinal cannabis formulations have been shown in independent third-party clinical laboratory tests to be effective in killing HER2 + breast cancer cells in 3D cell cultures through direct cytotoxicity.

The directors of the company accept responsibility for the contents of this release.

For more information, please visit www.apollon.org.uk or contact:

apollon@blytheweigh.com, +44 7875 744 070

Apollon formulas

Tel: +44 207 907 9314

Stene Jacobs stene@apollon.org.uk

Peterhouse Capital Limited (Management Advisor)

Tel: +44 207 220 9795

Guy Miller gm@peterhousecapital.com

Blytheweigh (Finance PR / IRLondon)

Tel: +44 207 138 3204

Tim Blythe tim.blythe@blytheweigh.com

Megan Ray megan.ray@blytheweigh.com

About Apollon and Apollon Jamaica

Apollon Formulies plc is an international medical cannabis pharmaceutical company headquartered in the UK. Apollon Formulies Jamaica, Ltd is a pharmaceutical company incorporated and operating in the Commonwealth of Jamaica and a contractual subsidiary of Apollon. Apollo Jamaica is licensed by the Jamaican Government’s Cannabis Licensing Authority (CLA) to purchase, process, conduct research and development, and sell cannabis medicinal products containing legal medicinal cannabis for various purposes from licensed breeders under tripartite agreements Treat illnesses under medical supervision.

SOURCE AfriAg Global Plc